TRAVERE THERAPEUTICS, INC. (TVTX)

Every figure this model derived for TVTX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 293,645,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 615,141,000 AssetsCurrent 2026-06-30
current liabilities 152,025,000 LiabilitiesCurrent 2026-06-30
equity 24,522,000 StockholdersEquity 2026-06-30
interest expense 9,481,000 InterestExpenseNonoperating 2026-06-30
ocf 37,784,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 591,331,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 60,661,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TVTX on one particular measure came for.

RatioValue
cash operating margin14.13
current ratio4.05
current ratio reported4.05
deferred revenue growth-60.33
dilution pct13.09
fcf margin6.39
growth cv1.71
interest cover-4.27
net debt ebitda0.79
operating margin-6.84
owner earnings margin-3.87
revenue growth77.12
revenue growth per share56.61
roic-75.03
rule of 4070.27
sbc pct revenue10.26

What to be careful about

What this model itself distrusts about TVTX's figures. Written by the derivation as it ran, not added afterwards.